Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
FONDAPARINUX SODIUM vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Category C
Category A/B
Anticoagulant
Anticoagulant